EntreMed/Bristol to study thalidomide for brain cancer in "near future" -- IPO prospectus.
Executive Summary
ENTREMED/BRISTOL TO BEGIN STUDIES OF THALIDOMIDE FOR BRAIN CANCER in the "near future," according to EntreMed's initial public offering prospectus. The studies in brain cancer will be similar to ongoing Phase II trials of oral thalidomide therapy to inhibit the progression of breast and prostate cancer and Kaposi's sarcoma, which are being conducted in collaboration with Bristol-Myers Squibb and the National Cancer Institute, the prospectus indicates. The offering netted proceeds of over $43.4 mil. for EntreMed ("The Pink Sheet" June 17, p. 14).